The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also touches on a study involving zinc and L-arginine.
Using Dutasteride as a hair loss treatment and its potential benefits, including availability in certain countries without a prescription and lower side effects than Minoxidil or RU58841.
Oral minoxidil can cause cardiovascular issues, but an extended release formulation may reduce side effects like heart rate and blood pressure spikes. This new formulation offers a safer option for those who previously had to stop due to health concerns.
The conversation discusses whether using 0.1% topical finasteride alongside 0.5 mg oral finasteride is excessive, with suggestions to choose either oral or topical treatment. The user also uses 5% minoxidil and mentions concerns about alcohol-based solutions due to seborrheic dermatitis.
A user on finasteride for 7+ months shared bloodwork results, questioning if high DHT levels and testosterone could affect cholesterol. Replies suggest consulting a doctor and question the high testosterone levels.
Finasteride raises total testosterone but lowers free testosterone, which is important for male health. Users report mixed experiences with their fitness levels and blood test results after using finasteride.
The conversation discusses the effectiveness of different doses of Dutasteride (Dut) in reducing scalp DHT levels. It suggests that 1mg and 1.5mg doses would reduce scalp DHT by amounts between 51% and 79%.
The conversation compares Finasteride and Dutasteride for hair loss treatment, discussing their effectiveness and side effects. Users share personal results and consider combining treatments like Dutasteride with RU58841.
Finasteride is being discussed as a significant treatment for male baldness, with some users sharing positive experiences and increased confidence, while others express concerns about potential side effects like loss of libido and erectile dysfunction. The conversation highlights differing opinions on the drug's impact and the broader societal implications of changing beauty standards.
A user is planning to get extensive blood tests before starting Finasteride and is seeking advice on which tests are necessary. They are concerned about the cost and potential redundancy of some tests.
Dutasteride at 0.5 mg and 2.5 mg doses may eventually yield similar hair growth results over time, with 0.5 mg being sufficient for many users. Higher doses may not significantly increase benefits and could lead to diminished returns.
The user is concerned about high DHT levels despite using finasteride and dutasteride for hair loss, suggesting these treatments may not be effective. They plan to consult an endocrinologist and consider other antiandrogens, acknowledging potential side effects.
The conversation discusses the effectiveness and potential side effects of using a minoxidil, finasteride, and biotin combination pill for hair loss, comparing half-dose (0.55mg Fin, 2.5mg Min, 0.5mg Biotin) to full-dose (1.1mg Fin, 5mg Min, 1mg Biotin). The user is considering whether to increase to a full dose after starting with a half dose.
Stress can trigger hair loss, with treatments like minoxidil, finasteride, and dutasteride being used to manage it. Some users report improvement with medications like Lexapro, while others emphasize the impact of stress and life events on hair health.
Users discuss the effectiveness of low-dose topical finasteride (0.005-0.05%) for hair loss, often combined with minoxidil. Some report stable results or new growth, but it's unclear if improvements are due to finasteride or minoxidil.
Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.
A user discusses a company, Roots by Genetic Arts, that offers a genetic test for hair loss to create personalized treatments, and is curious about its legitimacy and the science behind it. The company tests 16 genes related to hair loss and compounds a topical treatment based on the results.
The conversation discusses hair loss treatments, specifically finasteride, minoxidil, ketoconazole shampoo, and microneedling, with users experiencing initial success followed by increased shedding and regression. Many users suggest patience, as hair cycles can take years, and some attribute changes to seasonal shedding.
A 27-year-old male physician improved hair density using minoxidil 5% foam and finasteride 1mg every other day, with initial sexual side effects that subsided. He recommends trying finasteride for a year but warns against dutasteride due to potential liver effects.
RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.
Finasteride likely does not significantly affect beard growth. Some users report slowed beard growth, but many maintain their beards without noticeable changes.
The conversation humorously discusses the journey of deciding to use finasteride for hair loss, with a focus on a funny Facebook post. It also touches on the idea of promoting finasteride use to future generations.
A Dutasteride Simulator predicts serum dutasteride, serum DHT, and scalp DHT levels using models from research papers. It simulates various dosing schedules to determine steady-state effects and visualizes outcomes, including hair growth-related scalp DHT suppression.
A 22-year-old male experiencing diffuse hair thinning has been using finasteride, initially at 0.5mg and then 1mg daily, but sees no improvement. Despite correcting a vitamin D deficiency and noticing some new hair growth, he questions the effectiveness of finasteride.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
Adipose-derived stem cell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.
RU58841 is discussed as a hair loss treatment, with users considering lower doses like 2.5% to reduce costs. Some users suggest that if already blocking DHT, lower doses might still be effective unless there's high sensitivity to DHT.